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Abstract
Gene transfer of a human cocaine hydrolase (hCocH) derived from butyrylcholinesterase (BChE) by 5 mutations (A199S/
F227A/S287G/A328W/Y332G) has shown promise in animal studies for treatment of cocaine addiction. To predict the
physiological fate and immunogenicity of this enzyme in humans, a comparable enzyme was created and tested in a
conspecific host. Thus, similar mutations (A199S/S227A/S287G/A328W/Y332G) were introduced into mouse BChE to obtain
a mouse CocH (mCocH). The cDNA was incorporated into viral vectors based on: a) serotype-5 helper-dependent adenovirus
(hdAD) with ApoE promoter, and b) serotype-8 adeno-associated virus with CMV promoter (AAV-CMV) or multiple promoter
and enhancer elements (AAV-VIP). Experiments on substrate kinetics of purified mCocH expressed in HEK293T cells showed
30-fold higher activity (U/mg) with 3H-cocaine and 25% lower activity with butyrylthiocholine, compared with wild type
BChE. In mice given modest doses of AAV-CMV-mCocH vector (0.7 or 361011 particles) plasma hydrolase activity rose 10-
fold above control for over one year with no observed immune response. Under the same conditions, transduction of the
human counterpart continued less than 2 months and antibodies to hCocH were readily detected. The advanced AAV-VIP-
mCocH vector generated a dose-dependent rise in plasma cocaine hydrolase activity from 20-fold (1010 particles) to
20,000 fold (1013 particles), while the hdAD vector (1.761012 particles) yielded a 300,000-fold increase. Neither vector
caused adverse reactions such as motor weakness, elevated liver enzymes, or disturbance in spontaneous activity.
Furthermore, treatment with high dose hdAD-ApoE-mCocH vector (1.761012 particles) prevented locomotor abnormalities,
other behavioral signs, and release of hepatic alanine amino transferase after a cocaine dose fatal to most control mice
(120 mg/kg). This outcome suggests that viral gene transfer can yield clinically effective cocaine hydrolase expression for
lengthy periods without immune reactions or cholinergic dysfunction, while blocking toxicity from drug overdose.
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Introduction
Recent work in several laboratories has addressed the possibility
of treating cocaine addiction with ‘‘interceptor proteins’’ that block
cocaine’s access to brain reward centers [1]. The aim of such a
therapy would be to reduce the risk of relapse into drug-taking
provoked by cocaine re-encounter. This could be accomplished by
antibody binding (via vaccination) or by metabolic destruction (via
enzyme delivery). We have focused on the latter approach,
specifically using viral gene transfer to deliver a human
butyrylcholinesterase (BChE) optimized for cocaine hydrolysis by
previously reported active-site mutations [2,3,4]. The general
feasibility of using this cocaine hydrolase (CocH) was established in
rat studies showing that CocH gene transfer can suppress drug-
primed reinstatement of cocaine-seeking behavior for at least six
months [5]. Further work indicates that a combined therapy using
anti-cocaine vaccine along with CocH gene transfer might be even
more effective than either single treatment [6].
As these studies were progressing, research focused on natural
human BChE as a prophylactic against chemical warfare agents
showed that this enzyme is physiologically benign [7,8,9]. In
accord, we have not yet seen any toxicity in mice or rats receiving
CocH injections or expressing CocH after viral gene transfer. Our
accumulated data do indicate, however, that rodents develop
antibodies against human BChE and CocH, which speed
clearance of these transduced proteins and lower their plasma
levels. This is to be expected because human BChE shares only
80% sequence identity with its rodent counterparts [10]. Antibody
responses should be less likely in patients undergoing an enzyme-
based therapy for cocaine abuse because only five amino acid
residues distinguish CocH from natural BChE. Nonetheless, if
such reactions did occur, they would curtail or impair the effect of
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treatment. Our chief goal in the present study, aiming toward a
future clinical trial of gene transfer, was to determine whether the
particular mutations conferring high activity against cocaine as a
substrate could constitute an immunologic stimulus. Such an
outcome would justify increased caution regarding safety and
efficacy. A second goal, also in preparing for application in
humans, was to begin comparing two different vector platforms in
terms of efficacy and potential toxicity. Finally, to address a
speculative concern, a last goal was to determine whether high
plasma levels of CocH might impair cholinergic function by virtue
of the enzyme’s retained ability to hydrolyze acetylcholine,.
In order to evaluate these issues in an animal model, we
generated a comparable cocaine hydrolase based upon murine
BChE (mCocH) and incorporated it into viral gene transfer vectors
for testing in mice. Here we report: 1) catalytic properties of
mCocH with cocaine and the ‘‘conventional’’ BChE substrates,
acetylcholine and butyrylthiocholine; 2) enzyme plasma levels and
turnover rate after transduction in vivo by adeno-associated and
helper-dependent adenoviral vectors using different promoter
systems; 3) duration of expression and tests of antibody responses;
4) effect on locomotor responses to cocaine administration; and 5)
liability for toxicity or tissue damage as reflected in levels of
sentinel enzymes from liver, heart, and skeletal muscle.
Results
Enzyme Substrate Kinetics
Mutated mouse BChE cDNA, A199S/S227A/S287G/
A328WY332G (mCocH), was incorporated into adeno-associated
viral vector (AAV8) and helper-dependent adenoviral vector
(hdAD) as described in METHODS. To obtain protein for
enzyme kinetics studies, HEK293T cells were transfected with
AAV shuttle plasmid and enzyme was purified from culture
supernatants. After active site titration with DFP (Fig. 1), a study of
enzyme kinetics with 3H-cocaine, butyrylthiocholine, and acetyl-
choline as substrates was carried out. The results (Table 1) showed
that mCocH had nearly 10-fold greater catalytic efficiency with
cocaine (kcat/Km = 7.1) than wild-type mouse BChE (kcat/
Km = 0.86). In contrast, mCocH showed reduced efficiency with
butyrylthiocholine: apparent Km and Vmax = 99 mM and 330 U/
mg, compared with 72 mM and 420 U/mg for wild type enzyme.
The mutated enzyme also exhibited definite substrate inhibition
instead of the substrate activation usual with wild-type BChE.
Thus the altered amino acid residues appear to have created a
secondary binding site for butyrylthiocholine that did not lead to
hydrolysis but blocked access to the active site. Possible structural
explanations for this effect are under investigation.
Indefinitely Sustained Transduction After Low dose Viral
Vector
Although mCocH was 100-fold less efficient than human CocH
at hydrolyzing cocaine [2,3], a gene transfer still raised plasma
cocaine hydrolase activity at least an order of magnitude. This
effect enabled us to examine the duration of transduction as well as
the protein turnover rate and plasma half-life, key measures of
in vivo stability. For the purpose, groups of four and twelve mice,
respectively, were given AAV-CMV-mCocH vector in i.v. doses of
0.7 or 361011 viral particles, and blood samples were tested
periodically for cocaine hydrolase activity. The activity from
endogenous mouse BChE (pre-injection or untreated control
samples) was 0.1 mU/ml, but in vector-treated animals, cocaine
hydrolysis rose 10 to 30 fold over the next two weeks (Fig. 2A).
Furthermore, elevated levels continued indefinitely with only slight
reduction over an extended period (respectively 15 and 22 months
to date, still continuing). Thus, in practical terms, gene transfer
supported near-lifetime expression of the mutant hydrolase. In
contrast, 10 mice transduced with human CocH by the same AAV-
CMV vector platform (1011 viral particles) expressed that foreign
enzyme for only a few weeks (Fig. 2B). This curtailed expression
Figure 1. Purification of murine BChE (mBChE). A) SDS-PAGE gel
with single major protein bands after purification of wild type mouse
enzyme and the cocaine hydrolase mutant (mCocH); B) Active-site
titration of mCocH with diisopropylfluorophosphate.
doi:10.1371/journal.pone.0067446.g001
Table 1. Summary of kinetic constants for hydrolysis of
cocaine, acetylcholine (ACh), and butyrylthiocholine (BThCh)
by wild type mouse BChE as previously determined [14,15]
and mCocH, determined as described in Methods.
WT mBChE mCocH
BThCh ACh Cocaine BThCh ACh Cocaine
Km (mM) 72 400 1.6 99 210 35
Vmax (U/mg) 420 460 0.01 330 230 3.0
kcat (min
21) 35,600 38,400 1.4 28,200 19,000 250
kcat/Km 490 96 0.86 285 90 7.1
Given constants are mean values of three or more experiments. Standard error
of determination was typically 30% or less of the constant value.
doi:10.1371/journal.pone.0067446.t001
Mutant Mouse Cholinesterase Gene Transfer
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e67446
was associated with immunological responses (see below), which
may have accelerated the enzyme’s degradation.
Molecular Forms and Plasma Half-life of Transduced
mCocH
On ultracentrifugation native mouse BChE sediments mainly as
an 11S tetramer generated by interaction between proline-rich
attachment domains (PRAD) and small polyproline peptides [11].
However, in a separate study (Geng, Gao, Brimijoin and Zhan,
unpublished data) transduced mouse CocH sedimented as a 6.5 S
dimer. Since BChE dimers are typically less stable than BChE
tetramers, we attempted to estimate the in vivo turnover rate of the
transduced protein from the recovery of enzyme activity after
irreversible inhibition. This inhibition was accomplished with the
organophosphate anticholinesterase, iso-OMPA, highly selective
for BChE’s active site serine residue. Mice were given iso-OMPA
(50 mg/kg, i.p.) approximately 6 weeks after injection of AAV-
CMV-mCocH vector (361011 particles) or saline solution. In both
groups, iso-OMPA decreased BChE activity by 95% within 5 hr,
without indications of cholinergic toxicity. Because in vitro tests
indicated that enzyme in plasma samples directly exposed to iso-
OMPA did not reactivate spontaneously during prolonged dialysis
(up to 48 hr), we used the time course of in vivo recovery as an
index of replacement by newly synthesized enzyme (Fig. 3). The
t1/2 for recovery of mouse CocH activity in vector-treated mice
was 46610 hr. In comparison native BChE activity in control
mice recovered with t1/2 = 110625 hr. Thus, the mutated enzyme
was slightly less stable in vivo than the native protein. The greatly
elevated enzyme level and slightly reduced enzyme half-life imply
a very large increase of BChE synthesis in vector-treated mice (in
mg of enzyme protein/day).
Low Immunogenicity of mCocH
One factor that might shorten the in vivo half-life of mCocH
would be an immune response. To address that possibility, blood
sampled from vector-transduced mice across a range of times was
screened for antibodies against mCocH. The tests (see Methods)
utilized an assay previously found to have high specificity and
sensitivity to detect enzyme-directed immunoglobulins, both IgG
and IgM [12]. Positive control samples were taken from mice
transduced with human CocH, which was expected to be
immunogenic. In these animals, a brief period of expression was
followed by abrupt decline to baseline as already noted. Plasma
samples taken at 4 to 6 weeks gave a strong signal for anti-BChE
antibody, averaging 300 times the near-zero baseline values in
untreated control mice (Table 2). The same assay failed to detect a
statistically significant signal from mice transduced with the
conspecific mutant, mCocH, either during the initial peak of
activity (at 3 weeks), or subsequently (3 and 8 months). Although
this outcome did not definitively establish a complete absence of
immune responses, it indicated that the mutations in mouse BChE
were at most weakly immunogenic and relatively inaccessible to
the host immune system. This finding has favorable implications
for therapeutic applications involving other active-site BChE
mutants, as will be discussed later.
Dose-response Relations for mCocH Transduction with
AAV Vector
It was of interest to determine whether enzyme expression with
AAV vector could be enhanced with more effective regulatory
elements. For that purpose we compared mCocH transduction by
AAV-CMV with a recently reported ‘‘high efficiency’’ AAV-VIP
vector [13] of the same serotype (see Methods). The results
indicated that AAV-VIP at a dose of 1011 particles was almost 10-
fold more effective than AAV-CMV at equivalent or higher doses
(Fig. 4A). Therefore most subsequent experiments with AAV
vector utilized this new construct.
When multiple doses of the AAV-VIP mCocH vector were
compared, the plasma level of mouse CocH activity showed a
strong dose-dependency that was stable over a two-month period
of examination (Fig. 4B). At the top dose (1013 viral particles)
activity was more than 10,000-fold above the level in untreated
mice. After this study, mice from one dose group (1012 particles)
were euthanized, and tissue samples were examined by QPCR to
determine viral copy numbers in relation to measured enzyme
activities (Fig. 5). Liver was by far the major locus of viral particles
(4100670 copies per ng of genomic DNA) and liver homogenates
displayed by far the highest level of CocH activity (80 mU/mg).
The next most abundant location was diaphragm muscle (200638
copies/ng). No significant level of vector was detected in heart,
lung, spleen, brain, pancreas, kidney, or whole blood, and the
Figure 2. Expression of mouse and human CocH with AAV
vector. A). Mice were treated with either of two different i.v. doses of
AAV-CMV-mCocH vector: 761010 viral particles (filled circles, n = 4) or
361011 viral particles (open circles, n = 12). Other mice were given
empty vector or saline treatment. Shown are cocaine hydrolase
activities (mU/ml) in plasma samples at the indicated times (data from
control mice are not represented because cocaine hydrolysis was barely
measurable, less than 0.1 mU/ml). Note duration approaching 2 years.
B). AAV-CMV-hCocH vector (1011 viral particles) was administered
(n = 10), and cocaine hydrolase activities were monitored during the
comparatively brief expression (time scale in weeks).
doi:10.1371/journal.pone.0067446.g002
Mutant Mouse Cholinesterase Gene Transfer
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e67446
minor amounts of CocH activity in homogenates of these tissues
were attributed to blood residues despite aortic perfusion.
Very High Expression After High-dose hdAD Vector
To explore the range of cocaine hydrolase transduction with a
different vector platform, ten mice were injected with hdAD-
vector encoding the same mouse CocH sequence. Because low
doses had proved less than optimal, mice were given 1.761012
viral particles i.v. Surprisingly, plasma cocaine hydrolase activity
rose to a peak value of 25 U/ml (Fig. 6), , 10,000-fold above the
1 to 3 mU/ml obtained in the early AAV experiments and
280,000-fold above the baseline value in untreated control mice.
Total activity against butyrylthiocholine rose less, approximately
1000-fold, corresponding to a 1500-fold rise in enzyme protein
after allowing for its reduced efficiency with that substrate. From
multi-species studies of BChE activity and kinetics [14,15,16] we
estimated the level of native BChE in normal mouse plasma at 5 to
6 mg/ml, and we therefore calculated a rise to 8 mg/ml in the
transduced subjects. The high-level expression of BChE activity
was well maintained, remaining near 15 U/ml for the whole
observation period (9 months to date). In contrast, measurements
of plasma acetylcholinesterase (AChE) showed no disturbance
from the control mouse level of 0.5 U/ml.
Absent Locomotor Response to Cocaine in Hydrolase-
transduced Mice
Our previous experience showed that direct injection of cocaine
hydrolase based on human BChE (hCocH) reduced or completely
suppressed a wide variety of responses to cocaine [5,12,17,18,19].
To confirm that over-expression of mCocH acts in similar fashion,
mice from the high-dose hdAD group were tested in hour-long
sessions in an automated locomotor activity chamber. These
animals exhibited no excess ambulation or other behavioral signs
when challenged with a strongly stimulating dose, of cocaine,
40 mg/kg, i.p. (Fig. 7). This suppressant effect was specific to
cocaine, as the animals responded robustly to the related
stimulant, D-amphetamine, not a substrate for mCocH. In a
follow-up experiment to probe the limits of protection, the same
mice were given cocaine at much higher dosage (120 mg/kg, i.p.).
No quantitative locomotor studies were performed in this case, but
close observation failed to identify any outward reaction from
these mice, such as tremors, gait abnormalities or other signs. In
Figure 3. Turnover of vector-delivered mCocH and native BChE. Mice treated 5 months beforehand with 361011 particles of AAV vector
encoding mCocH, and mice with no prior treatment, received 50 mg/kg of iso-OMPA at time zero, causing ,95% inhibition of plasma CocH/BChE
activities. Time-course of recovery was monitored as an index of replacement by newly synthesized enzyme. Relative rates are shown in activities as
percent of pre-treatment levels.
doi:10.1371/journal.pone.0067446.g003
Table 2. Anti-BChE antibodies detected by immunoprecipitation.
Untreated controls (n=10) AAV-CMV-hCocH (n=9) AAV-CMV-mCocH (n =16)
Age – 1–2 months 1–8 months
CocH binding (arbitrary units) 20613 5,95061,280*** 132687
Treated mice received AAV viral vector encoding mouse BChE mutated for enhanced cocaine hydrolysis (mCocH), or human BChE with comparable mutations (hCocH).
Data represent cocaine hydrolase activity adsorbed by anti-mouse IgG and IgM antibodies coupled to a solid-phase matrix (see Methods). Bound activity is expressed in
arbitrary units directly proportional to the amount of cocaine-hydrolyzing enzyme. All mice transduced with the human protein, hCocH, gave a strong signal (***,
p,0.001). The 16 mice transduced with the murine equivalent, mCocH, gave no significant signal as a group, though one sample was borderline.
doi:10.1371/journal.pone.0067446.t002
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PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e67446
comparison, unprotected mice were prostrated by the overdose
and several died.
Toxicological Studies
Liver is a predominant target both for AAV-VIP and hdAD-
ApoE vectors, and most transduction of mutant BChE takes place
in that tissue as demonstrated previously [12] and confirmed here.
Therefore, in mice given high doses of hdAD or AAV vectors
Figure 4. Effect of vector promoter and vector dose on mCocH expression. A) Mice were given injections of AAV-CMV-mCocH vector
(361011 viral particles) or AAV-VIP mCocH vector (1011 viral particles). Plasma samples were collected at the indicated time points and assayed for
cocaine hydrolysis activity. Means and standard errors of the means are shown (n= 12). B) Mice received AAV-VIP-mCocH vector in the indicated
doses, and cocaine hydrolase activity was measured repeatedly from 2 weeks to 2 months. Data, in mU, are reported on a logarithmic scale. Means
and standard errors are shown (n= 10 per group).
doi:10.1371/journal.pone.0067446.g004
Figure 5. Quantitative PCR evidence for liver as primary site of vector. Mice were euthanized 2 months after i.v. injection of AAV-VIP vector
with mutated BChE at a dose of 1012 viral particles per animal. Vector DNA in the indicated tissues was quantitated by qPCR and expressed as viral
genome copies per ng of host DNA.
doi:10.1371/journal.pone.0067446.g005
Mutant Mouse Cholinesterase Gene Transfer
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transducing high mCocH expression, we investigated plasma
alanine aminotransferase (ALT), a sentinel indicator of liver
damage. ALT activities in both vector groups were low normal at
3 weeks (data not shown) and at 3 months (Table 3). Furthermore,
24 hr after these mice received the 120 mg/kg cocaine overdose,
their plasma ALT remained at the level of saline treated controls.
Figure 6. Extreme mCocH expression with high-dose hdAD vector. Mice (n = 10) were given vector injections of 1.761012 viral particles.
Circulating levels of cocaine hydrolase activity are shown (note ordinate scale in units (U) rather than milliunits).
doi:10.1371/journal.pone.0067446.g006
Figure 7. Spontaneous and stimulant-induced locomotor activity in control mice and mice transduced with mCocH by high-dose
hdAD vector. Subjects (n = 8 to 12) were tested in locomotor activity chambers 6 weeks after receiving hdAD-mCocH vector. Controls were
previously untreated animals. Shown are means and SEM of locomotor activity (cm traveled per 2-min bin) from hour-long sessions on consecutive
days beginning immediately after injection of saline (days 1–3), cocaine 40 mg/kg (day 4), and D-amphetamine 5 mg/kg (day 7). One-way analysis of
variance indicated a highly significant difference between treatment groups (F = 10.6, p,0.001). Statistical significance of the most relevant
significant pairwise multiple comparisons is indicated by asterisks (* t .3.1, p,0.01; ** t .3.8, p,0.001). The complete analysis is available in
Supplementary Materials (Table S2).
doi:10.1371/journal.pone.0067446.g007
Mutant Mouse Cholinesterase Gene Transfer
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In comparison, non-transduced animals challenged in the same
manner showed a roughly 400-fold increase in ALT activity
indicative of severe pathology and hepatic necrosis. Thus by this
measure the high dose vector treatments were not only non-toxic
themselves, they were able to protect mice against a near-lethal
hepatotoxic insult from cocaine.
Two months later similar experiments were performed on the
same mice in order to evaluate vector toxicity in cardiac and
skeletal muscle. For this purpose, plasma levels of troponin-I from
skeletal and cardiac muscle were selectively determined by ELISA
before and 24 hr after cocaine (Table 3). Before drug challenge
both measures were low in the vector-treated groups (mean values
non-significantly below control). Thus, as with liver, there was no
evidence of vector-related toxicity in either of these contractile
tissues. After cocaine challenge in saline pretreated mice, skeletal
muscle troponin-I rose dramatically, by almost the same multiple
as ALT activity (Table 3). The data did not follow a normal
distribution but the increase was highly significant (p,0.01) by
Mann-Whitney test and by standard t-test after log transformation.
This sign of cocaine toxicity was abolished in mice pretreated with
either of the CocH-transducing viral vectors. Cardiac-specific
troponin I was not detectable in plasma samples from any of the
tested groups, including those receiving cocaine with or without
vector treatment.
Discussion
These experiments addressed the potential immunogenicity of
the mutations in murine BChE conferring high catalytic efficiency
with cocaine. The results indicate that the suite of five mutations
under study, optimal or near optimal for cocaine hydrolysis [2,3],
does not constitute an "immunological signature" that provokes a
strong antibody response. All but one of 16 mice transduced with
viral vector for the pentavalent-mutant transgene, mCocH,
developed no antibody detectable with a sensitive pull-down assay
(the exception gave a weak reaction). In contrast, the assay readily
measured anti-BChE antibodies in virtually all mice transduced
with the equivalent human protein. This outcome was anticipated
because most of the altered residues in mCocH sit deep in the
enzyme’s catalytic gorge and may well be shielded from immune
surveillance. Nonetheless, these supportive animal data should
help establish the clinical safety of a proposed gene transfer
therapy with modified human BChE.
The modified mouse enzyme’s weak antigenicity probably
explains the contrast between the indefinite duration of mCocH
transduction versus four weeks for its human equivalent, which
provoked an antibody response under present conditions in mice,
though not previously in rats [5]. It is also worth noting that this
long term expression was matched by good in vivo stability of
mCocH, judging by the rate of recovery of activity after
irreversible inhibition. This outcome is somewhat surprising since
the mutant enzyme was expressed primarily in the form of dimers
rather than tetramers, the more stable and typically dominant
form. One likely reason for the relatively low degree of
oligomerization is a limited availability of the proline rich peptides
(PPrPs) that are required for cholinesterases to form tetramers
[20]. These peptides are more abundant in humans [21].
Therefore, CocH transduction in a clinical setting may lead to
more stable tetramers that accumulate to higher levels at any given
rate of biosynthesis.
A dramatic finding was the high final level of circulating cocaine
hydrolase after a large dose of hdAD vector, associated with a
nearly 300,000-fold increase in cocaine hydrolyzing activity and
an estimated 1500-fold increase in BChE protein. This increase
moved BChE in these animals from "minor" to "major" serum
protein, nearly as abundant as albumin. We are unaware of a
comparable result in previous gene transfer studies. However, the
noticeable difference in enzyme levels with the two vectors
probably reflects many factors. Therefore, these data are not a
strong basis for determining which vector is best for clinical use. It
is critically important to make that determination before
entertaining a clinical trial. At present there is a general sense
that AAV vectors are safer than hdAD, and a growing number of
gene therapy trials rely on this platform [22,23]. Two crucial
questions to resolve in choosing AAV or hdAD for future CocH
gene transfer in humans are: 1) Can we shrink the difference in
enzyme transduction by these agents at equivalent viral loads? 2)
Which will transduce more protein at an acceptable level of
toxicity? The data reported here with hdAD and AAV-VIP
represent a step towards resolving question one.
Given the impressive expression of mCocH, which also
hydrolyzes acetylcholine, the lack of physiological abnormality in
mice is remarkable. Our finding of normal spontaneous locomotor
activity suggests that very high plasma BChE activity does not
impair neuromuscular function. This agrees with prior research on
BChE’s physiological impact. Thus, studies evaluating human
BChE as prophylaxis against chemical warfare agents found no
autonomic or motor impairment in rats, guinea pigs or primates,
even with gram doses raising plasma enzyme levels 50–100-fold
[7,8,9,24,25,26]. This result could have been predicted. First, the
molar concentrations of acetylcholinesterase (AChE) and BChE in
blood (plasma plus red cells) are roughly similar [14] and, as AChE
is more catalytically efficient [27], a 10-fold increase in circulating
BChE only triples acetylcholine hydrolysis. Second, cholinergic
synapses in the brain are insulated from plasma enzymes by the
blood-brain barrier. Third, peripheral cholinergic synapses are
densely packed with AChE. Anglister’s classical morphometric
measures of cholinesterase density using 125I-fasciculin labeling
Table 3. Biomarker tests of liver, muscle and heart toxicity in vector-treated animals.
Saline Cocaine
Pretreatment Saline (n=8) hdAD-mCocH (n=8) AAV-mCocH (n=10) Saline (n=8) hdAD-mCocH (n=8) AAV-mCocH (n=10)
ALT activity 16.468.9 22.167.4 21.067.9 790061560** 20.562.4 11.660.7
SkM-Tn-I 4.661.8 3.361.3 3.160.63 3076180 * 5.362.5 1.260.2
Mice were pretreated i.v. with one of two viral vectors as indicated: a) hdAD encoding mCocH (1.761012 viral particles), or b) AAV-VIP encoding the human CocH (1013
viral particles). At the same time, control mice received saline injection or no treatment. Three to four months after pretreatment, a saline injection was given and
plasma samples were assayed 24 hr later for these biomarkers: ALT (alanine aminotransferase activity, U/L), skeletal muscle troponin-I (SkM-Tn-I, ng/ml), and cardiac
troponin-I (C-Tn-I, ng/ml). A week later the same mice were challenged with a large dose of cocaine (120 mg/kg i.p.), and the biomarkers were re-determined after
24 hr. Note the 500-fold rise of plasma ALT in unprotected subjects, ** (p,0.001), and the 66-fold rise of SkM-Tn-I, * (p,0.01 by Mann-Whitney test).
doi:10.1371/journal.pone.0067446.t003
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indicated 561019 catalytic AChE subunits per cc (, 0.1 mM) in
mouse neuromuscular junction [28]. In comparison mouse plasma
BChE levels are below 0.1 mM [14]. Since BChE hydrolyzes
acetylcholine half as efficiently as AChE, thousands-fold more
would be needed to match the synaptic capacity for ACh-
hydrolysis. Hence, even high levels of plasma BChE are unlikely to
affect motor transmission. Remaining areas for potential concern
are nicotinic synapses in peripheral autonomic ganglia and
muscarinic synapses with parasympathetic innervation. Investiga-
tions of cardiovascular function in vector-treated mice are
underway to address such issues.
ALT and troponin-I screening in mice with abundant mCocH
levels revealed no adverse effects of gene transduction per se in
liver, skeletal muscle or heart and indicated protection of liver and
skeletal muscle from large cocaine doses. That outcome matches
our previous findings with direct delivery or gene transfer of human
CocH [29]. The similar levels of protection were surprising since
hCocH hydrolyzes cocaine more efficiently than mouse CocH
[2,3]. However, total plasma enzyme concentration was substan-
tially greater in the current experiments. Current data do not
allow us to conclude that mCocH gene transfer will also protect
against cocaine-induced cardiotoxicity, because the cocaine
challenge did not affect cardiac troponin-I in unprotected mice.
Ongoing cocaine experiments in vector-naı¨ve mice, however,
confirm that repeated dosing will cause measureable release of
troponin-I from heart. These unpublished results serve as a
positive control for further experiments to determine whether
vector treatment will prevent cardio-toxicity.
If gene transduction of CocH or a similar enzyme reaches
clinical trial or enters clinical practice, it must use lower levels of
viral vector. The main reason will be to avoid acute toxicity from
agents that, even though nonpathogenic and non-replicating,
contain viral antigens that provoke host immune reactions [30,31].
Lower levels of vector imply lower enzyme expression. Therefore,
the present results indicate that expected levels of BChE
expression will pose no real added risk. The important question
is whether those levels will reduce responses to cocaine and lower
its reward value sufficiently to be therapeutic. If not, there is still
reason for optimism that cocaine hydrolase gene therapy
combined with anti-cocaine vaccine will be helpful to recovering
cocaine addicts.
There is a large literature on vaccines against drugs of abuse.
Such vaccines can generate substantial titers of high-affinity
antibodies against psychoactive small molecule haptens conjugated
to appropriate carrier proteins such as keyhole limpet hemocyanin
(KLH), cholera toxin (CTB) [32], and tetanus toxoid (TTX) [33].
Moderately encouraging results have been obtained with vaccines
to cocaine, as well as heroin, nicotine, and methamphetamine
[34,35,36,37]. Thus, several studies have found reduced drug
levels in plasma or brains of rodents with high titers of specific
drug antibody [38,39,40,41]. A clinical trial of anti-cocaine
vaccine indicated partial therapeutic effects in the form of
increased frequency of drug free urines [42]. Such effects were
related to the antibody titers, which varied substantially among
individuals, precluding a statistically significant effect overall.
Better results should follow further improvements in vaccine
technology.
Recent studies, in collaboration with Kosten and Orson at
Baylor, supported the concept of synergy between these two
treatment modalities. In particular, the combination of anti-
cocaine antibodies elicited by a nor-cocaine conjugate vaccine [43]
and cocaine hydrolase delivered either by direct i.v. enzyme
injection or by gene transfer proved particularly effective in
preventing muscle weakness and liver damage [29]. The same
combination also was super-additive in reducing stimulatory
locomotor responses and the behavioral sensitization that typically
follows repeated cocaine exposures [19]. In a recent review article
[1] we discussed the advantages and limitations of such treatments
in greater depth, including possible susceptibility to higher drug
doses and reduction of overdose risk. In our view, the accumulated
data strongly support continued efforts toward developing
enzyme-based gene transfer therapies along with more effective
vaccines for cocaine abuse.
Materials and Methods
Animal Subjects and Ethics Statement
Adult male mice (Balb/c),, 25 g in weight, were obtained from
Harlan Laboratories, Madison Wisconsin, under protocol A26810
(approved by the Mayo Clinic Institutional Animal Care and Use
Committee). All experiments were conducted in accordance with
the Guide for Care and Use of Laboratory animals [44] in a
facility accredited by the American Association for the Accredi-
tation of Laboratory Animal Care. Drugs were injected i.p. in
isotonic saline solution. Viral vectors were delivered by rapid
injection through the tail vein in an initial volume of 200 ml
followed by 200 ml of 0.9% sterile NaCl solution.
Chemicals, Drugs, and Reagents
Cocaine HCl was obtained from the National Institute of Drug
Abuse (Research Triangle Institute, Research Triangle Park, NC
USA). This drug was freshly dissolved in 0.9% NaCl for each
mouse experiment at a concentration that allowed delivery of
200 ml per 30 g (typical subject weight). D-amphetamine sulfate,
butyrylthiocholine iodide, tetraisopropylphosphoramide (iso-
OMPA), diisopropylfluorophosphate (DFP), and other reagents
including Pansorbin were purchased from Sigma-Aldrich (St Louis
MO).
Blood Collection, Enzyme Assay and Cocaine
Determinations
Blood samples (,0.1 ml) were taken from mice by cheek
puncture using a 21-gauge mouse-bleeding lancet. A sterile gauze
pad was then applied with slight pressure for about a minute to
stop bleeding. Blood samples were centrifuged for 15 min in serum
separator tubes (Becton Dickenson, Franklin Lakes, NJ, USA) at
8000 g and the sera were stored at 220˚ C before analysis of
antibody and CocH enzyme levels. Cocaine hydrolase activity in
duplicate 50-ml aliquots of serum was assayed by incubating
30 min with 3H-cocaine (50 nCi, 18 mM; Perkin Elmer, Boston
MA) and measuring liberated 3H-benzoic acid after acidification
and partition into toluene-based fluor for scintillation counting as
described previously [45].
Viral Gene Transfer
Mutations of enzyme cDNA were initiated with a method based
on adeno-associated virus as previously described [46,47,48]. First,
wild type mouse BChE cDNA (provided by S. Camp and P.
Taylor, UCSD) was cloned into a pAAV-CMV shuttle plasmid for
serotype 8 adeno-associated virus (AAV) gene transfer vector. A
Kozak consensus sequence (GCCACC) was introduced above the
translational start site. With this construct as template, site-
directed mutagenesis using primers with specific base-pair
alterations generated the mouse BChE mutant here termed
mCocH, A199S/S227A/S287G/A328W/Y332G (for primer
sequences see supplementary material, Table S1). The mCocH
DNA was also incorporated into a newly reported ‘‘AAV-VIP"
vector’’ [13] with enhanced transduction efficiency from a CMV
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enhancer, a chicken beta-actin promoter and a ubiquitin
promoter. To construct the plasmids for mCocH, recognition
sites for ‘‘Not I’’ and ‘‘BamH I’’ were introduced directly before
the Kozak consensus sequence and after the stop codon,
respectively. Subsequently, mCocH was ligated into a "pAAV-
VIP" plasmid between Not I and BamH I.
To produce and purify AAV8 viral particles, the plasmids
pAAV-CMV-BChE (wt or mCocH) or pAAV-VIP-mCocH were
co-transfected into HEK293T cells with helper vectors, pHelper
and pAAV2/8, using FuGene HD Transfection Reagent (Roche).
Three days later, AAV8 virus was purified from the cell lysates by
ultracentrifugation against Optiprep Density Gradient Medium-
Iodixanol (Sigma-Aldrich, St Louis MO). The concentration of
viral particles was subsequently determined by real-time quanti-
tative PCR (QPCR), which was also used to establish the tissue
distribution of delivered vector.
The mCocH cDNA was also incorporated into a serotype-5
helper dependent adenoviral vector (hdAD) under regulation by a
human ApoE hepatic control region [49], with a bovine growth
hormone polyadenylation sequence cloned into a derivative of the
p28lacZ hdAD-backbone plasmid. Vector was propagated using
the AdNG163 helper virus, as described [50], and particle titers
were determined by optical density at 260 nm. Helper virus
contamination, determined by plaque assay on HEK-293 cells,
was , 0.2% for both loaded and empty vectors.
Determining Viral Copy Numbers in Mouse Tissues
Total DNA was isolated from heart, lung, spleen, pancreas,
brain, kidney, diaphragm, hind limb muscle, liver and whole blood
using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
and quantitated by absorbance at 260 nm. Real time polymerase
chain reaction assays (QPCR) were performed in a 20-ml volume
comprising 1X iQ SYBR Green Supermix (BIO-RAD), 10 ng of
tissue DNA and 0.1 mM of each AAV-VIP-specific primer
(forward: 59-AACGCCAATAGGGACTTTCC-39; reverse: 59-
GGGCGTACTTGGCATATGAT-39). The PCR profile was
95uC for 3 min followed by 39 cycles of 95uC for 10 sec and
55uC for 30 sec. A standard curve was generated using serial
dilutions of pAAV-VIP-mCocH plasmid DNA to determine
genome copies of AAV8-VIP-mCocH in tissues and the results
were analyzed with SDS2.3 software (Applied Biosystems, Foster
City, CA).
In vitro Enzyme Expression and Enzyme Purification and
Substrate Kinetics
Three days after transfecting HEK293T cells with AAV-
plasmid encoding mCocH or wild type mouse BChE, enzyme
was isolated from the culture supernatants by procainamide-
Sepharose gel chromatography (gift from Dr. O. Lockridge, Univ.
Nebraska), followed by ion-exchange chromatography. Purifica-
tion led to a single major band on SDS polyacrylamide gel
electrophoresis (Fig. 1). Active sites were titrated with DFP to
determine final molar enzyme concentration as described previ-
ously [51]. Cocaine substrate kinetics were tested across a wide
range of concentrations using the radiometric assay described
above. Comparable experiments with acetyl- and butyrylthiocho-
line used the classic Ellman spectrophotometric assay [52]. To
estimate Vmax, Km, Kss, and ‘‘b’’, kinetic data were fitted to a
modified Michaelis-Menten equation with Sigma Plot (Version
11.0, Systat Software) as described [15,16].
Detection of CocH Antibodies
Immunoadsorption with Protein-A-bearing Staphylococcus aureus
cells (‘‘Pansorbin’’, EMD Biosciences Inc., La Jolla CA) was used
to screen for IgG or IgM antibodies to mCocH. Linker antibodies
against mouse IgG and IgM (Thermo Scientific, Rockford IL) at a
concentration of 0.24 mg/ml were adsorbed to Pansorbin aliquots
for 1 hr at 37uC. After buffer rinsing the pellets were re-suspended
and exposed 1 h at 37uC to 100 ml plasma samples plus 150 ml of
50 mM sodium phosphate, pH 7.4, followed by 3 cycles of buffer
washes and centrifugation at 2000 g for 10 min. These prepara-
tions along with any adsorbed mouse antibody were then tested for
ability to bind or inactivate cocaine-hydrolyzing protein during a
1 h exposure to a standard sample of transduced plasma. Binding
was evaluated by measuring the loss of cocaine hydrolase in
supernatants and appearance of that activity in pellets re-
suspended after a final centrifugation at 2000 g. Bound hydrolase
activity versus 3H-cocaine as substrate was arbitrarily expressed as
counts per min (cpm) per 100 ml sample in a 30 min assay.
Biomarker Assays for Vector-driven Toxicity in Liver,
Heart, and Skeletal Muscle
Liver toxicity was evaluated from plasma levels of alanine
transaminase (ALT) activity, measured spectrophotometrically by
the modified Wrobleski assay [53] with kit TR71121 from Thermo
scientific, Middletown, VA. In brief, mouse sera with or without
dilution were mixed with assay reagents (L-alanine and 2-
oxolglutarate) in the presence of lactic acid dehydrogenase and
NADH. Sample absorbance was then read at 340nm for 10 min in
a Molecular Dynamics Plate Reader. Activity above blank (saline
in place of serum) was expressed in U/L. Toxicity in heart and
skeletal muscle was evaluated by enzyme-linked immunoassays
specific for the forms of troponin-I in each tissue, using
spectrophotometric kits with horseradish peroxidase detection
(KT-470 and KT 472, Kamiya Biomedical Company, Seattle,
WA). Data were obtained in ng/ml.
Statistical Methods
Normally distributed data were analyzed by standard t-test or
one way analysis of variance with post-hoc testing by Fisher’s
PLSD. Data that failed preliminary tests of normality were
analyzed by the non-parametric Mann-Whitney test and by t-test
after conversion to a log scale. With the behavioral data, a one way
analysis of variance was conducted and, in light of the high
significance of treatment effects, all possible pairwise comparisons
were examined by the Holm-Sidak method, using an overall
significance level of 0.05.
Supporting Information
Table S1 Oligomeric primers for mutagenesis of mouse
butyrylcholinesterase. The indicated primer pairs were used
to make specific mutations in mouse BChE to generate a murine
enzyme containing the identical pentameric suite of active site
amino acids previously found to confer optimal catalytic efficiency
in cocaine hydrolysis by human BChE.
(DOCX)
Table S2 Detailed statistical analysis of locomotor
behavior. All possible pairwise comparisons of locomotor
behavior in different treatment groups were analyzed by analysis
of variance. Key points to note are: 1) highly significant effects of
treatment with hdAD vector on responses to cocaine but not on
responses to amphetamine; 2) lack of significant difference
between hdAD-treated mice given cocaine and control mice given
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saline; 3) lack of difference between control mice given saline and
hdAD treated mice given saline.
(DOCX)
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